SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-068801
Filing Date
2023-12-07
Accepted
2023-12-07 16:07:22
Documents
46
Period of Report
2023-10-31

Document Format Files

Seq Description Document Type Size
1 10-Q kalv-20231031.htm   iXBRL 10-Q 1146034
2 EX-3.1 kalv-ex3_1.htm EX-3.1 87921
3 EX-31.1 kalv-ex31_1.htm EX-31.1 16487
4 EX-31.2 kalv-ex31_2.htm EX-31.2 14722
5 EX-32.1 kalv-ex32_1.htm EX-32.1 10049
  Complete submission text file 0000950170-23-068801.txt   4230202

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT kalv-20231031_cal.xml EX-101.CAL 44493
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT kalv-20231031_def.xml EX-101.DEF 64331
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kalv-20231031_pre.xml EX-101.PRE 170075
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kalv-20231031.xsd EX-101.SCH 28499
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kalv-20231031_lab.xml EX-101.LAB 252080
40 EXTRACTED XBRL INSTANCE DOCUMENT kalv-20231031_htm.xml XML 633376
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 10-Q | Act: 34 | File No.: 001-36830 | Film No.: 231472427
SIC: 2834 Pharmaceutical Preparations